Tolerability, efficacy and recommended phase II dose (RP2D) of tepotinib plus gefitinib in Asian patients with c-Met-positive/EGFR-mutant NSCLC: Phase Ib data.
Year: 2016
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Guangdong General Hospital, Guangdong Academy of Medical Sciences, National University Cancer Institute, Singapore, National University Health System, Seoul National University Hospital, National Taiwan University Hospital, Merck KGaA, Darmstadt (Germany), Samsung Medical Center, Sungkyunkwan University
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2496670484